Original Research Paper
A Comparative Study On Safety Of Terbinafine And Griseofulvin In Patients With Tinea Corporis
Dr. G. Muthu Kavitha, Dr. C. Umamaheshwari
BACKGROUND: The treatment of dermatophytosis usually involves the use of topical or oral antifungal agents. Due to poor compliance of our patients, they may not adhere to prolonged oral medication. They should receive oral antifungal agents which are more safer with a short course of therapyAIM AND OBJECTIVES: To compare the safety of Terbinafine and Griseofulvin in patients with Tinea Corporis in a Tertiary care Hospital, MaduraiMATERIALS AND METHODS: About 60 patients are selected from the OPD of Dermatology according to inclusion & exclusion criterias. They were divided into 2 groups of 30 patients each. Group 1 received Tab. Terbinafine 250mg OD and group 2 received 250mg BD for 4 weeks. All patients were investigated at baseline, end of 2nd week and at end of 4 weeks. Safety profile was assessed by occurrence of adverse drug effects. The results were recorded, tabulated and analysed using students t test.RESULTS:.In our study, Griseofulvin treated patients have experienced more adverse effects such as headache 66.6%, vomiting 20%, peripheral neuritis13.3%, photosensitivity 16.6% heartburns 23.3%, and rashes 6.6%,vomiting 10%, heartburns13.3%. Terbinafine is found to be superior to griseofulvin in our study.CONCLUSION: Oral Terbinafine is the safest antifungal agent in the treatment of extensive tinea corporis infection when compared to griseofulvin.
Cite This Article :
Article :View PDF Article No. : 1Number of Views : 271